>>>In Wednesday's market monitor at OptionInvestor.com we mentioned that there was some trader talk that Teva Pharmaceutical (NASDAQ:TEVA) $77.43 might be added to the NASDAQ-100. This proves true as the Israeli generic drug maker will join the NASDAQ-100 Index (NDX.X) effective at the beginning of trading November 7, replacing Concord EFS (NASDAQ:CEFT) $14.28, which is moving its listing to the NYSE. Salomon Smith Barney expects indexers to sell a total of 21.5 million CEFT shares and purchase 3.4 million TEVA shares.